Lung Cancer Clinical Trial
Official title:
Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?
Verified date | April 2015 |
Source | The Miriam Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This study compares the effects of a standard smoking cessation treatment, including one-time brief counseling and provision of nicotine patch plus an 8-week moderate intensity exercise program versus the same standard smoking cessation treatment plus equivalent contact control among 60 healthy women. We hypothesize that participants in the smoking cessation plus moderate intensity exercise condition will be more likely to quit smoking than participants in the smoking cessation treament plus contact control condition.
Status | Completed |
Enrollment | 59 |
Est. completion date | December 2008 |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Healthy sedentary smokers (> 4 per day for at least one year) - Ages 18 to 65 years - Must be able to give informed consent - Must live in the area for the next 3 months - Willing to use the nicotine patch to attempt smoking cessation - Must receive consent to participate from primary care physician Exclusion Criteria: - Cannot read or write fluently in the English language - Pregnancy or plans to attempt pregnancy - 60 minutes or more per week of moderate or vigorous physical activity - Smokes cigars, pipes, or uses smokeless tobacco at least once per week - Currently in a quit smoking program - Currently using NRT of any kind or using any other quit smoking method or treatment - Never had an adverse reaction to the nicotine patch resulting in discontinuation of use - Poor willingness or inability to comply with protocol requirements - An employee of the Centers for Behavioral and Preventive Medicine - Previous participant in Commit to Quit or Fit to Quit smoking cessation studies - Another member of the household is or has been enrolled in this study - Currently taking a medication that might impact heart rate response, including but not limited to: Acebutolol Atenolol Carvedilol Metoprolol Nadolol Pindolol Propranolol Timolol Medical problems: - Cardiac disease of any kind such as angina, a history of myocardial infarction or valve disease including mitral valve prolapse. Anyone with an interventional procedure such as a stent - Pain, discomfort (or other anginal equivalent) in the chest, neck, jaw, arms or other areas that may be due to ischemia - Cerebrovasular disease such as stroke or history of transient ischemic attacks - Peripheral vascular disease (such as claudication) - Diabetes (both Type I and II) - Chronic infectious disease (HIV, hepatitis) (hepatitis A is okay) - Liver disease - Cystic fibrosis (CF) - Chronic obstructive pulmonary disease (COPD) (see asthma and bronchitis under questionable) - Interstitial lung disease - Emphysema - Chronic Bronchitis - Orthopnea (difficulty breathing except in the upright position) or paroxysmal nocturnal dyspnea (sudden shortness of breath at night typically triggered by lying down) - Current diagnosis of Chronic Fatigue Syndrome - Current diagnosis of Fibromyalgia - Abnormal exercise stress test - Hypertension (anyone currently being followed and/or treated for hypertension) - Cancer treatment (other than skin cancer) within the past 6 months - Musculoskeletal problems such as osteoarthritis, gout, osteoporosis or back, hip or knee pain that can interfere with physical activity (i.e., walking at a brisk pace - about 3-mph) - Any other serious medical condition that might make exercise unsafe or unwise Psychiatric Problems - Hospitalization for a psychiatric disorder in the last 6 months - Currently suicidal or psychotic, (or suicidal/psychotic in last 6 months) - Self-report of more than three alcoholic drinks per day on 5 or more days; 5 or more alcoholic drinks on 3 or more days - Taking these specific medications for psychiatric problems: Mood stabilizer (Lithium, Depakote, Neurontin), Antipsychotics (Haldol, Clozaril, Risperdal) - Must be on other current psychiatric medications for at least three months REQUIRES MD CONSENT FOR THE SPECIFIC CONDITION - Lightheadedness, dizziness, vertigo, or fainting - Last electrocardiogram (EKG) performed was abnormal - Anemia - Previous ETT for medical reason with normal results - Irregular heart beats or palpitations in the past two years - Heart murmurs in the past two years - the person will need physician's consent and an echocardiogram showing no evidence of significant heart disease |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | The Miriam Hospital | Providence | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
The Miriam Hospital | National Cancer Institute (NCI) |
United States,
Williams DM, Dunsiger S, Whiteley JA, Ussher MH, Ciccolo JT, Jennings EG. Acute effects of moderate intensity aerobic exercise on affective withdrawal symptoms and cravings among women smokers. Addict Behav. 2011 Aug;36(8):894-7. doi: 10.1016/j.addbeh.201 — View Citation
Williams DM, Whiteley JA, Dunsiger S, Jennings EG, Albrecht AE, Ussher MH, Ciccolo JT, Parisi AF, Marcus BH. Moderate intensity exercise as an adjunct to standard smoking cessation treatment for women: a pilot study. Psychol Addict Behav. 2010 Jun;24(2):3 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 7-day point prevalence smoking abstinence verified by saliva cotinine taken | post-intervention (8 weeks after baseline) | No | |
Secondary | 7-day point prevalence smoking abstinence verified by saliva cotinine | taken one month post-intervention (12 weeks after baseline) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|